Cckansas.cancercenter.cc

CURRICULUM VITAE
SHAKER R. DAKHIL, M.D., F.A.C.P.

Office Address:
Office Phone:

Present Position:
President, Cancer Center of Kansas, P.A.
EDUCATION:
Undergraduate
Graduate
St. Joseph University School of Medicine, Beirut, Lebanon Postgraduate
University of Michigan School of Medicine, Ann Arbor, MI
PROFESSIONAL CERTIFICATION:

ACADEMIC APPOINTMENTS:
The University of Kansas School of Medicine - Wichita, Wichita, KS
HOSPITAL APPOINTMENTS:
Via Christi Regional Medical Center, Wichita, KS Curriculum Vitae
Shaker R. Dakhil, M.D. - page 2
Hospital appointments - continued

MEDICAL LICENSURE:
Kansas, FLEX, active, #18826
MEDICAL SOCIETY MEMBERSHIPS:

PROFESSIONAL ORGANIZATIONS:
American Society of Clinical Oncology American Society of Hematology American Society of Internal Medicine Kansas Society of Clinical Oncology
ADMINISTRATIVE APPOINTMENTS:
Wichita Community Clinical Oncology Program Wichita Community Clinical Oncology Program National Surgical Adjuvant Breast & Bowel Project Curriculum Vitae
Shaker R. Dakhil, M.D. - page 3

HONORS:
Graduated first in medical school class of 68 Recipient of the first Harry Hynes Award for Excellence in
COMMUNITY SERVICE:
BIBLIOGRAPHY

Scientific papers submitted but not yet accepted:
1.
Palesh O, Mustain K, Heckler C, Purnell J, Peppone L, Weiss M, Atkins JN, Dakhil SR, Spiegel D, Morrow G: A phase III randomized prospective trial of the effect of psychotherapy on distress in 287 prostate cancer patients: A URCC CCOP study (U9994). (submitted to ASCO as abstract 1/09) Ryan JL, Heckler C, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR: Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients. (submitted to ASCO as abstract 1/09). Hines SL, Sloan JA, Atherton P, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Loprinzi CL: Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhil SR: Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group study N0074. Loprinzi CL, Qin R, Flynn KA, Balcueva EP, Rowland KM, Graham DL, Erwin NK, Dakhil SR, Jurgens DJ, Burger KN: A phase III, randomized, double-blind, placebo-controlled evaluation of Pregabalin for alleviating hot flashes, N07C1. Kim GP, Foster NR, Oberg AL, Jaslowski AJ, Alberts SR, Flynn PJ, Dakhil SR, Mowat RB, Garneau SC: NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma, N034A. Submitted to Cancer June 2009. Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson D, Mattar BI, Moore DF, Nikcevich D, Loprinzi CL: A randomized comparison of standard weekly epoetin alfa to every 3-week epoetin alfa and every 3-week darbepoetin alfa: A study of the Mayo Clinic Cancer Research Consortium (MCCRC). Submitted to ASH as abstract July 2009. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL: Tetracycline for epidermal growth factor receptor inhibitor-induced skin rash: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton P, Rowland KM, Bearden JD, Johnson DJ, Bernath AM, Soori GS, Flynn PJ, Loprinzi CL: Long acting methylphenidate for cancer-related fatigue: A phase III, randomized, double-blind placebo controlled study, NCCTG trial N05C7. (January 2010). Scientific papers with single or multiple authors (peer reviewed): 1. Dakhil S, Ensminger W, Kindt G, Niederhuber J, Chandler W, Greenberg H, Wheeler R: An implanted
system for intraventricular drug infusion in CNS tumors. Cancer Treat Rep 1981;65(5-6):401-411.
Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R: A totally implanted drug delivery system for
hepatic arterial chemotherapy. Cancer Treat Rep 1981 June;65(5-6):393-400.
Curriculum Vitae
Shaker R. Dakhil, M.D. - page 4
Scientific papers with single or multiple authors (peer reviewed con’t):
3.
Greenburg HS, Ensminger WD, Seeger JF, Kindt GW, Chabdker F, Doan K, Dakhil SR: Intra-arterial
BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: A preliminary
report. Cancer Treat Rep 1981(9-10):803-810.
Gyves J, Ensminger W, Niederhuber J, Liepman M, Cozzi E, Doan K, Dakhil S, Wheeler R: Totally
implanted system for intravenous chemotherapy in patients with cancer. Am J Med 1982;73(6):841-845.
Dakhil S, Ensminger W, Cho K, Niederhuber J, Doan K, Wheeler R: An improved regional selectivity of
hepatic arterial BCNU with degradable microspheres. Cancer 1982;50(4):631-635.
Housholder DF, Hynes HE, Dakhil SR, Marymont JV: Hepatobiliary scintigraphy in patients receiving
hepatic artery infusion chemotherapy. J Nucl Med 1985 May;26(5):474-477.
Marymont JV, Dakhil SR, Travers H, Housholder DF: Chemical cholecystitis associated with hepatic
arterial chemotherapy delivered by a permanently implanted pump. Hum Pathol 1985 Oct;16(10):986-990.
Ernst R, Chang F, Hynes HE, Dakhil SR, Farha GJ: An implantable drug delivery system. Kans Med 1986
July;87(7):198-200.
Grever MR, Benedetti J, Balcerzak SP, Taylor SA, Miller TP, Dakhil SR: A Southwest Oncology Group
phase II evaluation of fludarabine monophosphate in sarcoma. Invest New Drugs 1994;12:259-261.
Shin DM, Holoye PY, Forman A, Winn R, Perez-Soler R, Dakhil S, Rosenthal J, Robert MN, Hong WK:
Phase II clinical trial of didemnin-B in previously treated small cell lung cancer. Invest New Drugs
1994;12(3):243-249.
Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin G:
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients
with pancreatic adenocarcinoma. Cancer 1992 Oct 15;70(80):2073-2076.
Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, Loyer E,
Rusinkiewicz J, Gacrama P, Fueger R, Kavanaugh J: Activity of Paclitaxel in Advanced or Recurrent
Squamous Cell Cancer of the Cervix. Clin Cancer Res 1996;2:1285-1288.
Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, LoCoco S,
Umbreit J, Delmore JE, Arbuck S, Loyer E, Gacrama P, Fueger R, Kavanagh JJ: An update of a phase II
study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-Cancer Drugs 8:657-
661.
Samer E. Kaba, Athanassios P. Kyritsis, Kenneth Hess, W.K. Alfred Yung, Richard Mercier, Shaker
DakhilKurt A. Jaeckle, and Victor A. Levin: TPDC-FuHu Chemotherapy for the Treatment of Recurrent
Metastatic Brain Tumors. Journal of Clinical Oncology, Vol 15, No 3 (March), 1997: pp 1063-1070.
Pandya KJ, Flynn PJ, Dakhil SR, Rosenbluth RJ, Kirshner JJ, Pierce HI, Raubertas RF: Oral Clonidine in Postmenopausal Breast Cancer Patients with Tamoxifen-Induced Hot Flashes. A URCC CCOP Study. Pazdur R, Medgyesy DC, Winn RJ, Dakhil SR, Moore Jr. DF, Scalzo A, Hoff PM, Arbuck SG, Abbruzzese
JL: Phase II Trial of 9-aminocamptothecin (NSC 603071) administered as a 120- hour continuous infusion
weekly for three weeks in metqastatic colorectal carcinoma. Investigational New Drugs 1999 16:341-346.

Curriculum Vitae
Shaker R. Dakhil, M.D. - page 5

Scientific papers with single or multiple authors (peer reviewed con’t):
17.
Taylor SA, Girouz DJ, Jaeckle KA, Panella TJ, Dakhil SR, Schold SC: Phase II Study of Didemnin B in
Central Nervous System Tumors. A Southwest Oncology Group Study. Investigational New Drugs
16:331-332, 1999.
Holcombe RF, Jacobson J, Dakhil SR, Stewart RM, Betzing KS, Kannan K, Macdonald JS: Association of
immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group
Protocol 9009. Cancer Immunol Immunother 48:533-539 1999.
Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR,
Rodger K, Rummans TA, Christensen BJ: Venlafaxine in management of hot flashes in survivors of breast
cancer: a randomized controlled trial. Lancet 2000;356:2054-2063.
Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA, Dakhil SR, Crawford DE,
Hussain M: A Phase II Trial of Estramustine and Etoposide in Hormone Refractory Prostate Cancer: A
Southwest Oncology Group Trial (SWOG 9407). The Prostate 2001;46:257-261.
List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, Dakhil SR, Appelbaum FR:
Cyclosporine Inhibition of P-Glycoprotein in Chronic Myeloid Leukemia Blast Phase. Blood 2002;
100(5):1910-1912.
Klein CE, Tangen CM, Braun TJ, Hussain MHA, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR,
Crawford ED: Evaluation of Topotecan in Hormone Refractory Prostate Cancer: A Southwest Oncology
Group Study (SWOG-9510). The Prostate 2002;52:262-268.
Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode LM, Dakhil SR, Crawford ED: Phase II
Trial of Recombinant Human Interleukin-4 in Patients with Advanced Renal Cell Carcinoma: A Southwest
Oncology Group Study. Journal of Immunotherapy 2002; 25(4):352-358.
Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Dakhil SR, Krook FE, Buckner JC, Fitch TR,
Wiesenfeld M, Mailliard JA: Gemcitabine and Oxaliplatin for Patients with Advanced or Metastatic
Pancreatic Cancer: A North Central Cancer Treatment Group (NCCTG) Phase I Study. Annals of Oncology
2002; 13:553-557.
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch
TR, Krook JE, Novotny PJ, Christensen B: Dronabinol Versus Megestrol Acetate Versus Combination
Therapy for Cancer-Associated Anorexia. A North Central Cancer Treatment Group Study (NCCTG).
Journal of Clinical Oncology 2002; 20(2):567-573.
Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier K,
Chapman RA, Fisher RI: Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV
Low-Grade Lymphoma: S9501. Journal of Clinical Oncology 2003; 21(10):1996-2003.
Hickok JT, Roscoe JA, Morrow GR, Bushunow P, Shelke AR, Matteson S, Dakhil SR, Flynn PJ:
Occurrence of Severe Nausea in 194 Women Treated with Doxorubicin for Breast Cancer. Supportive
Care in Cancer 2003; 11:393-394.
Jatoi A, Ellison NM, Burch PA, Sloan JA, Dakhil SR, Novotny PJ, Tan WW, Fitch TR, Rowland KM,
Young CYF, Flynn PJ: A Phase II Trial of Green Tea in the Treatment of Androgen-Independent Metastatic
Prostate Cancer. Cancer 2003; 97:1442-1446.

Curriculum Vitae
Shaker R. Dakhil, M.D. - page 6

Scientific papers with single or multiple authors (peer reviewed con’t):
29.
Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS,
Chapman RA, Fisher, RI: Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV
Low-Grade Lymphoma. Journal of Clinical Oncology 2003;21(10):1996-2003.
Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh
BJ, Jaffe AS: Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients
with breast cancer in the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. Journal
of Clinical Pathology 2004;22(18):3700-3704.
Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides DS, Crowley JJ,
Gandara DR: Phase I study of Tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in
limited-stage small cell lung cancer (S0004): A Southwest Oncology Group Study. Clinical Cancer
Research 2004;10:5418-5424.
Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan M, Fitch TR, Rowland KM, Kardinal CG, Krook JE,
Kugler JW, Dakhil SR: Randomized phase II study of two Irinotecan schedules for patients with metastatic
breast cancer refractory to an anthracycline, a taxane or both. Journal of Clinical Oncology
2004:22(14):2849-2855.
Jatoi A, Rowland KM, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard
JA, Bushey TI, Nair S, Christensen BJ: An eicosapentaenoic acid supplement versus megestrol acetate
versus both for patients with cancer-associated wasting. A NCCTG study and NCI of Canada collaborative
effort. Journal of Clinical Oncology 2004; 22:2469-2476.
Jatoi A, Egner JR, Loprinzi CL, Sloan JA, Novotny PJ, Dakhil SR, Mailliard JA, Klee FF, Krook JE:
Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss
trial. Supportive Care in Cancer 2004; 12:640-644.
Gotay CC, Moinpour CM, Jiang CS, Ankerst DP, Coleman D, Martino S, Taylor B, Bearden J, Dakhil S,
Gross H, Albain DS: Enhancing well-being during breast cancer recurrence: preliminary finding from a
phase III study. Breast Cancer Research and Treatment 88(Suppl 1):S140(#3080). (2004).
Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR: Phase II
trial of dolastatin-10 in patients with advanced breast cancer. Investigational New Drugs 2005; 23:257-
261.
Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton
RF, Dakhil SR, Gross H, Kaufman S: A phase II trial of single-agent Temsirolimus (CCI-779) for relapsed
mantle cell lymphoma. Journal of Clinical Oncology 2005; 23(23): 5347-5356.
Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR,
Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh D: Phase II trial of temsirolimus
(CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. Journal
of Clinical Oncology 2005; 23(23): 5294-5304.
Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore Jr DF, Krook JE,
Rowland KM, Mazurczak MA, Berg AR, Kim GP: Evaluation of shark cartilage in patients with advanced
cancer: a North Cancer Clinical Trial Group trial. Cancer 2005;104(2):176-182.

Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 7

Scientific papers with single or multiple authors (peer reviewed con’t):
40.
Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR: 5-
hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by
doxorubicin: a URCC CCOP randomized controlled trial. The Lancet 2005; (6): 765-772.
Amin BR, Hillman SL, Nikcevich DA, Dakhil SR, Mailliard JA, Fitch TR, Bernath A, Jett JR, Perez EA:
Randomized phase II study of docetaxel and gemcitabine for stage IIIB/IV non-small cell lung cancer: an
NCCTG study. Lung Cancer 2005.
Moreno-Aspitia A, Colon-Otero G, Hoering A, Tefferi A, Niedringhaus R, Vukov A, Li CY, Menke DM,
Geyer S, Alberts SR, Dakhil SR, Wos EJ, Morton RF, Fitch TR: Thalidomide therapy in adult patients with
myelodysplastic syndrome: a North Central Cancer Treatment Group phase II trial. Cancer 2005.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S,
Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G,
Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N:
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal
of Medicine, 353;16, 1673-1684.
Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD, Mailliard JA, Tschetter
LK, Fitch TR, Kugler JW: Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for
managing hot flashes: North Central Cancer Treatment Group Trial N99C7. Journal of Clinical Oncology,
24(9), 1409-1414.
Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K,
Nair S, Sargent DJ, Donohue JH: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable
liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study.
Journal of Clinical Oncology, 23(26): 9243-9249, 2005.
Gotay CC, Moinpour CM, Unger JM, Jiang CS, Coleman D, Martino S, Parker BJ, Bearden J, Dakhil SR,
Gross HM, Lippman SM, Albain KS: Impact of a peer-delivered telephone intervention for women
experiencing a breast cancer recurrence. Journal of Clinical Oncology 2006.
Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH: A
phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin and 5-fluorouracil in patients with advanced
or recurrent squamous cell carcinoma of the head and neck (SWOG S0007). Cancer, 107(2), 319-327.
Williamson SK, McCoy SA, Gandara DR, Dakhil SR, Yost KJ, Paradelo JC, Atkins JN, Glanke CD,
Abbruzzese JL: Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer. A Southwest
Oncology Group (SWOG) trial. American Journal of Clinical Oncology, 29(2): 116-122, 2006.
Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW,
Dakhil SR, Abbruzzese JL: A phase II trial of epothilone B analogue BMS-247550 (NSC#710428)
ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study.
Investigational New Drugs, 24:515-520, 2006.
Haberman TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B,
Fisher RI, Peterson BA, Horning SJ: Rituximab-CHOP versus CHOP alone or with maintenance rituximab
in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24(19): 3121-3127,
2006.

Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 8

Scientific papers with single or multiple authors (peer reviewed con’t):
51.
Sideras K, Schaffer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton
RF, Rowland KM, Novotny P, Loprinzi CL: Low-molecular-weight heparin in patients with advanced
cancer: A phase 3 clinical trial. Mayo Clinic Proceedings, 81(6):758-767, 2006.
Clark MM, Hurt RD, Croghan IT, Patten CA, Novotny P, Sloan JA, Dakhil SR, Groghan GA, Wos EJ,
Rowland KM, Bernath A, Morton RF, Thomas SP, Tschetter LK, Garneau S, Stella PJ, Ebbert LP, Wender
DB, Loprinzi CL: The prevalence of weight concerns in a smoking abstinence clinical trial. Addictive
Behaviors, 31:1144-1152 (2006).
Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD, Mailliard JA, Tschetter
LK, Fitch TR, Kugler JW: Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for
managing hot flashes: North Central Cancer Treatment Group trial N99C7. Journal of Clinical Oncology,
24(9):1409-1414. (2006).
Dy GK, Jett JR, Geoffroy FJ, Krewer KD, Tazelaar H, Maurer M, Rowland K, Mailliard J, Krook J, Dakhil
S, Kutteh L, Kugler J, Wender D: Topotecan and paclitaxel in previously treated patients with relapsed
small cell lung cancer: Phase II trial of the North Central Cancer Treatment Group. Journal of Thoracic
Oncology, 2006; 1(3):211-7.
Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K,
Crowley JJ, Gandara DR: Phase II trial of paclitaxel, carboplatin and topotecan with G-CSF support in
previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Journal of Thoracic Oncology, 1(9):991-995, 2006.
Giordano KF, Jatoi A, Stella PJ, Foster N, Tschetter LK, Alberts SR, Dakhil SR, Mailliard JA, Flynn PJ,
Nikcevich DA: Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and
gastroesophageal junction: A phase II study of the North Central Cancer Treatment Group. Annals of
Oncology, 2006; 17(4):652-6.
Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Dakhil SR, Kugler
JW, Windschitl HE, Rowland KM, Bernath AM, Fitch TR, Soori G, Jett JR, Adjei AA, Perez EA: Phase III
randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell
lung cancer after completion of initial therapy (NCCTG 97-24-51). Journal of Clinical Oncology 2006.
Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young
C, Tan W: A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer:
Results of a phase II study from the North Central Cancer Treatment Group. Urology 2007; 69(2):289-294.
Jatoi A, Nguyen PL, Foster N, Sun D, Stella PJ, Campbell M, Tschetter LK, Dakhil SR, Mailliard JA,
Nikcevich DA : Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight
loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. Journal of Supportive
Oncology, 5(1): 41-46, 2007.
Croghan I, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Wos EJ, Rowland KM, Nair S,
Morton RF, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi
CL: A randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse
prevention. Mayo Clinic Proceedings 2007 82(2):186-195.
Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 9

Scientific papers with single or multiple authors (peer reviewed con’t):
61.
Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM, Soori GS, Wender DB, Fitch TR,
Novotny PJ, Loprinzi CL: A placebo-controlled double blind trial of etanercept for the cancer
anorexia/weight loss syndrome; results from N00C1 from the North Central Cancer Treatment Group.
Cancer 2007.
Jatoi A, Burch P, Hillman D, Vanjo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C,
Tan W: A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer:
Results of a phase II study from the North Central Cancer Treatment Group. Urology, 2007, 69(2):289-294.
Haddock MG, Swaminathan R, Foster NR, Alberts SR, Hauge MD, Martenson JA, Fitch TR, Stella PJ,
Tenglin RC, Schaefer PL, Dakhil SR: Gemcitabine, cisplatin and radiation therapy for patient with locally
advanced pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II study, N9942.
Journal of Clinical Oncology 2007 25:2567-2572.
Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Verdirame JD, Nikcevich DA, Warner DO,
Novotny PJ, Kutteh LA, Dakhil SR, Wong GY: The efficacy of gabapentin in the management of
chemotherapy-induced peripheral neuropathy: A phase III randomized , double-blind, placebo-controlled,
crossover trial (N00C3). Cancer 2007.
Gotay CC, Moinpour CM, Unger JM, Jiang CS, Coleman D, Martino S, Parker BJ, Bearden JD, Dakhil SR,
Gross HM, Lippman S, Albain KS: Impact of a peer-delivered telephone intervention for women
experiencing a breast cancer recurrence. Journal of Clinical Oncology 25(15):2093-2099. (2007).
Petersdorf SH, Rankin C, Head DR, Terebelo HR, Willman CL, Balcerzak SP, Kamad A, Dakhil S,
Appelbaum FR: Phase II evaluation of an intensified induction therapy with standard daunomycin and
cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a
Southwest Oncology Group study (SWOG-9500). American Journal of Hematology 82:1056-1062.
(2007)
Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL,
Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas E,
Wolmark N: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project
protocols B-18 and B-27. Journal of Clinical Oncology 26(5):778-785. (2008).
Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW,
Martino S, Albain KS: Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on
Southwest Oncology Group (SWOG) protocol S8897. Journal of Clinical Oncology 28(8): 1223-1230.
(2008).
Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil
SR, Ingle JN, Winet EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ: Cardiac safety analysis of
doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central
Cancer Treatment Group N9831 adjuvant breast cancer trial. Journal of Clinical Oncology 28(8): 1231-
1238. (2008).
Loprinzi CL, Barton DL, Sloan JA, Novotny PJ, Dakhil SR, Verdirame JD, Knutson WH, Kelaghan J,
Christensen BJ: Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20 year
experience. Journal of the North American Menopause Society 15(4 pt 1): 655-660. (2008).
Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 10
Scientific papers with single or multiple authors (peer reviewed con’t):
71.
Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Dakhil SR, Kugler
JW, Windschitl HE, Rowland KM, Bernath AM, Fitch TR, Soori G, Jett JR, Adjei AA, Perez EZ: Phase III
randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell
lung cancer after completion of initial therapy (NCCTG 97-24-51). Lung Cancer 60(2): 200-207. (2008)
Halyard MY, Pisansky TM, Dueck AC, Pierce L, Solin LJ, Marks LB, Davidson NE, Martino S, Kaufman
PA, Kutteh LA, Dakhil SR, Perez EA: Radiotherapy and adjuvant trastuzumab in stage I-IIA breast cancer:
Tolerability and adverse event data from the North Central Cancer Treatment Group Phase 3 trial N9831.
Journal of Clinical Oncology 27: 2638-2644 (2009).
Kearns AE, Northfelt DW, Dueck AC, Atherton PJ, Dakhil SR, Rowland KM, Fuloria J, Flynn PJ,
Dentchev T, Loprinzi CL: Osteoporosis prevention in prostate cancer patients receiving androgen ablation
therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Support Care Cancer
(published online: May 27, 2009)
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman
Cl, Kopecky KJ, Appelbaum FR. Sequential phase II Southwest Oncology Group studies (S0112 and
S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older
patients with previously untreated acute myeloid leukaemia. British Journal of Haematology 10.1111/j.
1365-2141. (2009)
Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S,
Gorton S, Pautret V, Weber MR, Woytowitz D. Cetuximab and first-line taxane/carboplatin chemotherapy
in advanced non-small cell lung cancer: Results of the randomized multicenter phase III trial BMS099.
Journal of Clinical Oncology 28(6): 911-927 (2010).
Loprinzi CL, Qin R, Balcueva EP, Flynn KA, Rowland KM, Graham DL, Erwin NK, Dakhil SR, Jurgens
DJ, Burger KN. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for
alleviating hot flashes, N07C1. Journal of Clinical Oncology 28(10): 1808 (2010
Boccia RV, Cosgriff TM, Headley DL, Badarinath S, Dakhil SR. A phase II trial of FOLFOX6 and
cetuximab in the first-line treatment of patients with metastatic colorectal cancer. Clinical Colorectal
Cancer 9(2): 102-107. (2010)
Other scholarly publications - Abstracts: 1. Dakhil S, Ensminger W, Kindt G: Maintenance of constant CSF MTX levels with a totally implanted infusion system. Proceedings of the American Association for Cancer Research (AACR) 1980;21:149. 2. Greenberg H, Ensminger W, Seeger JF, Kindt G, Dakhil S: Escalating doses of intracarotid BCNU for malignant gliomas. Clin Res 1980 Oct;28:743A.
3. Ensminger W, Dakhil S, Cho K: Improved regional selectivity of hepatic arterial BCNU plus degradable starch microspheres. Proceedings of the American Society for Clinical Oncology (ASCO) 1981;22:382. 4. Keller J, Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R: Effective prolonged hepatic arterial chemotherapy using a totally implanted delivery system. Proceedings of the ASCO 1981;22:178, C87. Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 11

Other scholarly publications - Abstracts – (continued) 5. Dakhil S, Ensminger W, Strother V, Kindt G, Chandler W, Greenberg H: Pharmacokinetics of intraventricular 5-fluoro-2'deoxyuridine (Fudr) in patients with meningeal neoplasia. Proceedings of the AACR 1981;22:178, C706. 6. Ensminger W, Dakhil S, Doan K, Cho K: Clinical Pharmacology of dichloromethotrexate in hepatic arterial infusions. Proceedings of the AACR 1981;22:271, C1077. 7. Housholder D, Hynes H, Dakhil S, Marymont J: Hepatobiliary scintigraphy in patients receiving hepatic artery infusion chemotherapy. Society of Nuclear Medicine, 1984,June;
8. Dakhil S, Zatzkin J, Kim P, Hynes H: Digital subtraction angiography in the evaluation of malpositioned hepatic artery catheter. Proceedings of the ASCO 1984;3:C-542. 9. Dakhil S, Hynes H, Kim P, Zatzkin J: Wichita community experience with the Infusaid pump for chemotherapy of liver malignancies. Proceedings of the American College of Physicians Kansas Regional Meeting, Kansas City, Missouri, February 1983. 10. Dakhil S, Hynes H, et al: Secobarbital combination, an effective antiemetic regimen in patients receiving platinum. Proceedings of the ASCO 1985;4:270, C1049.
11. Dakhil S, Hynes H, Zatzkin J: Wichita community experience with the implantable catheter (Port-A-Cath). Proceedings of the ASCO 1985;4:270, C1050.
12. Balducci, Dakhil S, et al: Evaluation of Fludarabine phosphate in renal cell carcinoma. Proceedings of the ASCO 1985;4:100, C429.
13. Morrow GR, Pandya K, Barry M, DiFino S, Jennings P, Flynn P, Rosenbluth R, Dakhil S: Chemotherapy- induced fatigue and patient-reported psychological depression (meeting abstract). Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1992, #A1329. 14. Dakhil SR, Hynes HE, Cannon MW, Johnson DB, Moore DF Jr: G-CSF plus ciprofloxacin in the prevention of sepsis in patients with severe neutropenia related to chemotherapy. Blood 1994;84(Suppl
1):24a(#83). Proceedings of the American Society of Hematology, 1994.
15. Moore DF Jr, Moore DF Sr, Johnson DB, Cannon MW, Whisman SA, Church PS, Palko W, Dakhil SR, Hynes HE: Bethesda unit titer as a prognostic factor for patients with acquired factor VIII inhibitors. Blood
1994;84(Suppl 1):680a(#2705).
16. Pazdur R, Bready B, Diaz-Canton E, Gray R, Belt W, Goodwin SR, Dakhil SR, Fueger R, Winn R, Ajani JA: Sequential modulation of fluorouracil with leucovorin, PALA, and alpha interferon: Phase II trial in advanced colorectal carcinoma. Proceedings of the ASCO 1995;14:208(#510). 17. Fossella FV, Lee JS, Winn R, Wester M, Graham S, Holder LW, Goodwin JW, Dakhil SR, Hong WK: Edatrexate (E) + Ifosfamide (I) + Cisplatin (P) with Leucovorin (LV) and Mesna (M) for advanced non-small cell lung cancer (NSCLC). Proceedings of the ASCO 1995;14:371(#1145). 18. Moore DF Jr, Moore DF Sr, Johnson DB, Bluml P, Cannon MW, Dakhil SR, Palko W, Hynes HE: Interleukin-2 (IL-2) therapy following autologous blood and marrow transplantation in Burkitt's lymphoma: effect on lymphocyte subsets. Proceedings of the 2nd Pan-Pacific Lymphoma Conference 1995, (abstr)[In Press]. Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 12
Other scholarly publications - Abstracts – (continued) 19. Whitehead RP, Blumenstein B, Flanigan RC, Weiss GR, Culkin DJ, Bearman SI, Dakhil SR, Crawford ED: Phase II trial of recombinant human interleukin-4 (rhuIL-4) in patients with disseminated renal cell adenocarcinoma: A Southwest Oncology Group (SWOG) Study. American Society of Clinical Oncology 1996; 15:259(#672). 20. Increased Intensification and Total Dose of cyclophosphamide in a Doxorubicin-Cyclophosphamide Regimen for the Treatment of Primary Breast Cancer: Findings from national Surgical Adjuvant Breast and
Bowel Project B-Special participation from Shaker R. Dakhil. Journal of Clinical Oncology, Vol 15, No 5
(May), 1997: pp 1858-1869.
21. Medgyesy, D., Dakhil, S., Moore, D., Scalzo, A., Hoff, P.M., Abbruzzese, J., Winn, R., Pazdur, R., M.D.Anderson Cancer Center, Houston, TX 77030, Wichita CCOP, Wichita, KS 67214, Syracuse CCOP, Syracuse, NY 13210. 9-AC Study; NCI-EORTC Symposium, 1998. 22. Loesch D, Robert N, Dakhil S, Gusfey G, Hopkins J, Rohrbaugh T: Phase II Trial of a Weekly Taxol (T), 5- Fluorouracil (FU) and Leucovorin (LV) Regimen in Patients (Pts) with Metastatic Breast Cancer: An Update. Presented at ASCO 1999;18:117a(#445). 23. Robert N, Loesch D, Dakhil S, Lee M, Rohrbaugh T: Phase II Trial of Weekly Taxotere (T), 5-Fluorouracil (FU), and Leucovorin (LV) in Patients with Advanced Breast Cancer. Presented at ASCO 1999;18:119a(#451). 24. Garfield D, Dakhil S, Abubakr Y, Druger S, Frank S: Phase II Trial of Carboplatin (CP) and Etoposide (E) Induction Therapy (IT) Followed By Weekly Taxol (T) Maintenance Therapy (MY) in Patients (pts) with Extensive Stage Small Cell Lung Cancer (ESSCLC). Proceedings of ASCO 1999;18:505a(#1945). 25. Hoff P, Ellerton JA, Dakhil SR, Winn RJ, Abbruzzese JL, Pazdur R: Phase II Study of Intravenous CI-958 in Metastatic Colorectal Adenocarcinoma. The University of Texas M.D. Anderson Cancer Center, Houston, Texas, Southern Nevada CCOP, and Wichita CCOP, Wichita, Kansas. 26. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Norton L, Allred C, Dakhil S, Pierce T, Goodwin J, Thompson I, Rivikin S, Chapman R, Osborne K: CMF Versus CAF With and Without Tamoxifen in High-Risk Node-Negative Breast Cancer Patients and A Natural History Follow-up Study in Low-Risk Node-Negative Patients. First Results of Intergroup Trial INT 0102. A Southwest Oncology Group Operations Office, San Antonio, Texas. 27. Hynes HE, Dakhil SR, Fisher EI, Coltman Jr CA, Godfrey MA: Phase II Trial of Estramustine and Etoposide in Hormone Refractory Prostate Cancer. A Southwest Oncology Group Trial (SWOG-9407). 28. Dakhil SR, Logie KW, Marsland TA, Simon SR, Weinstein RE, Khan MM: Phase II trial of doxil in patients with refractory/relapsed low grade non-Hodgkin’s lymphomas. American Society of Hematology. 2000. Abstract #4750. 29. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVassiur BI, Barton DL, Novotny PJ, Dakhil SR, Kardinal CG, Christensen BJ, Rodger K, Rummans T: Venlafaxine alleviates hot flashes (slide presentation) Proceedings American Society of Clinical Oncology 19:2a (2000).
Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 13
Other scholarly publications - Abstracts – (continued) 29. Hussein MA, Gundacker H, Elias L, Dakhil SR, Head DR, Applebaum FR: Encouraging Response Rate to Sequential Cyclophosphamide (Cy) Followed by Fludarabine Phosphate (FI) In Newly Diagnosed B-Cell Chronic Lymphocytic Leukemia (CLL): A Southwest Oncology Group Trial. Proc of the American Society of Clinical Oncology 2001;20:305a(#1217). 30. Alberts SR, Horvath W, Donohue JH, Sternfeld W, Goldberg RM, Mahoney MR, Nagorney DM, Levitt R, Dakhil SR, Rowland K, Sargent DJ: Oxaliplatin (OXAL), 5-Flurouracil (5FU), and Leucovorin (CF) for Patients with Liver Only Metastases from Colorectal Cancer: A north Central Cancer Treatment Group (NCCTG) Phase II Study. Proceedings of ASCO 20:129a, 2001. 31. Klein CE, Tangen CM, Braun TJ, Hussain M, Budd GT, Nichols CR, Rivikin SE, Dakhil SR, Crawford ED: Evaluation of Topotecan in Hormone Refractory Prostate Cancer: A South West Oncology Group Study. (SWOG 9510). 32. Hussein MA, Gundacker H, Elias L, Dakhil SR, Head DR, Appelbaum F: Encouraging response rate to sequential cyclophosphamide (CY) followed by fludarbine phosphate (FI) in newly diagnosed B-cell chronic lymphocytic leukemia (B-CLL): Proceedings of the American Society of Clinical Oncology, 20:305a(#1217), 2001. 33. Velasquez WS, Lew D, Grogan TM, Kuebler JP, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS, Chapman RA, Fisher RI: Combination of Fludarabine and Mitoxantrone in Untreated Stages III/IV Low-Grade Lymphoma: A Southwest Oncology Group Study (SWOG 9501). 34. Jatoi A, Dakhil S, Burch P, Mattar B, Sloan J, Fitch T, Novotny P, Camoriano J, Young C, Rowldand K, Quevedo F, Tan W: A Phase II Trial of Green Tea for Androgen-Independent Prostate Cancer. A North Central Cancer Treatment Group (NCCTG) Trial. 35. Perez EA, Hillman DW, Fishkin P, Krook JE, Alberts SR, Dakhil SR: Phase II Trial of Dolastatin-10 in Patients With Advanced Breast Cancer. A North Central Cancer Treatment Group and Mayo Clinic. 36. Jatoi A, Dakhil SR, Burch PA, Mattar BI, Sloan JA, Fitch TR, Novotny PJ, Camoriano JK, Young CY, Rowland KM, Quevedo F, Tan WW: A phase II trial of green tea for androgen-independent prostate cancer. A NCCTG trial. Proc Am Soc Clin Oncol 2002. 37. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Buckner JC, Fitch TR, Rowland, KM, Kugler JW, Dakhil SR: Randomized phase II study of two schedules of irinotecan (CPT-11) for patients with refractory metastatic breast cancer (MBC): An NCCTG study. Proc Am Soc Clin Oncol 2002;21:52a. 38. Burch PA, Alberts SR, Schroeder MT, Erlichman C, Dakhil S, Steen PD, Nair S, Cha S, Sargent DJ, Goldberg RM: Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma (ACA): A North Central Cancer Treatment Group (NCCTG) phase II study. Proceedings of the American Society of Clinical Oncology 2003, 22:259(1038). 39. Jatoi A, Rowland KM, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny CL, Mailliard JA, Krook JE: An eicosapentaninoic acid (EPA) – enriched supplement versus megestrol acetate (MA) versus both for patients with cancer-associated wasting. Proc Am Soc Clin Oncol 2003;22:743. 40. Alberts SR, Schroeder MA, Erlishman C, Steen PD, Dakhil SR, Rowland KM, Nair SC, Cha S, Sargent D, Goldberg R: Gemcitabine and ISIS-2503 for patients with pancreatic andenocarcinoma: a North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol 2003;22:259. Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 14
Other scholarly publications - Abstracts – (continued) 41. Alberts SR, Donohue JH, Mahoney MR, Horvath WC, Sternfeld WC, Dakhil SR, Levitt R, Rowland KM, Sargent DJ, Goldberg RM: Patterns of failure after liver resection in patients receiving FOLFOX4 for metastatic colorectal cancer limited to the liver: a North Central Cancer Treatment Group study. European Journal of Cancer 2003;Suppl 5:S80. 42. Alberts SR, Donohue JH, Mahoney MR, Horvath WC, Sternfeld WC, Dakhil SR, Levitt R, Rowland KM, Sargent DJ, Goldberg RM: Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. Proceedings of the American Society of Clinical Oncology 2003, 22:263(#1053). 43. Whitehead RP, McCoy S, MacDonald J, Rivkin SE, Neubauer M, Dakhil S, Lenz HJ, Tanaka M, Abbruzzese JL: Phase II Trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study. Proceedings of the American Society of Clinical Oncology 2003, 22:272(#1092). 44. Ranson S, Morrow GR, Dakhil S, Wade JL, Fitch T, Roscoe J, Shelke A, Hickok JT: Internet use among 1020 cancer patients assessed in community practices: A URCC CCOP study. Proceedings of the American Society of Clinical Oncology 2003, 22:534(#2149). 45. Jett JR, Geoffroy FJ, Rowland KM, Maurer MJ, Dakhil S, Krook J: Topotecan (T) and paclitaxel (P) in previously treated patients with refractory or relapsed small cell lung cancers (SCLC): A phase II trial of the North Central Cancer Treatment Group. Proceedings of the American Society of Clinical Oncology 2003, 22:667(#2681). 46. Jatoi A, Rowland KM, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Malliard JA, Krook JE: An eicosapentainoic acid (EPA)-enriched supplement versus megestrol acetate (MA) versus both for patients with cancer-associated wasting. A collaborative effort from the North Central Cancer Treatment Group (NCCTG) and the National Cancer Institute of Canada. Proceedings of the American Society of Clinical Oncology 2003, 22:743(#2987). 47. Schulz TK, Geyer SM, Jatoi A, Castillo R, Fitch TR, Dakhil SR, Rowland KM, Nair SR, Krook JE, Kugler JW: Oral vinorelbine in elderly patients (> 65 years old) with advanced non-small cell lung cancer (NSCLC): A phase II trial from the North Central Cancer Treatment Group. Proceedings of the American Society of Clinical Oncology 2003, 22:752(#3022). 48. Loprinzi CL, Levitt R, Barton D, Sloan J, Atherton P, Dakhil S, Nikcevich DA, Rowland KM, Tschetter LK, Mailliard JA, Fitch TR: Evaluation of Benefin Shark Cartilage in Patients With Advanced Cancer: A North Central Cancer Treatment Group (NCCTG) Trial. 49. Moreno-Aspitia A, Tefferi A, Niedringhaus R, Colon-Otero G, Vukov A, Li CY, Menke DM, Geyer S, Hoering A, Alberts SR, Dakhil SR, Wos EJ, Morton RF, Fitch TR: Thalidomide Therapy in Adult Patients With Myelodysplastic Syndrome: A North Central Cancer Treatment Group (NCCTG) Phase II Trial. 50. Worden FP, Moon J, Samlowski W, Clark J, Dahkil SR, Taylor SA, Urba SG, Hussain M: A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5-FU) in patients with advanced or recurrent squamous cell carcinoma of the head and neck (SCCHN). A Southwest Oncology Group (SWOG) study. Proc of the American Society of Clinical Oncology 23:489(#5512) (2004).
Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 15
Other scholarly publications - Abstracts – (continued) 51. Miller DV, Jenkins RB, Lingle W, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Perez EA: Focal HER2/new amplified clones partially account for discordance between immunohistochemistry and fluorescence in situ hybridization results. Proc American Society of Clinical Oncology 22:19s. (2004). 52. Kim GP, Alberts SA, Tschetter LK, Fitch TR, Dakhil SR, Morlan BW, Sargent DJ: Gemcitabine and docetaxel in patients with measurable unresectable or metastatic hepatocellular carcinoma. Proc American Society of Clinical Oncology 22:380s. (2004). 53. Call TG, Constantinou CL, Kahanic SP, Rowland KM, Dakhil SR, Hoering A, Li CY, Dewald GW, Kay NE, Witzig TE: Trial of gemcitabine for relapsed B-cell chronic lymphocytic leukemia. Proc American Society of Clinical Oncology 22:613s. (2004). 54. Goetz MP, Jatoi A, Geyer SM, Safgren SL, Kuffel MJ, Adjei AA, Castillo RA, Dakhil SR, Fitch TR, Ames MM: MDRI and CYP2A5 polymorphisms and clinical outcome in elderly patients treated with oral vinorelbine as first-line therapy for metastatic non-small cell lung cancer. AACR (2004). 55. Habermann, T.M., Weller, E., Morrison, V.A., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Gascoyne, R.D., Woda, B., Fisher, R.I., Peterson, B.A., Horning, S.J.: Rituximab-CHOP vs CHOP With or Without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update [abstract]. Am Soc Hematology 2004. Abstract 127. [E4494] 56. Witzig TE, Ansell SM, Geyer SM, Kurtin PJ, Rowland KM, Flynn PJ, Morton RF, Dakhil SR, Gross HM, Maurer MJ, Kaufmann SH: Antitumor activity of low-dose single agent CCI-779 for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group. Proc of the American Society of Clinical Oncology 23:561s (2005). 57. Wong GY, Michalak JC, Sloan JA, Mailliard JA, Nikcevich DA, Warner D0, Loprinzi CL, Kutteh LA, Dakhil SR: A phase III double-blinded, placebo controlled randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy. Proc of the American Society of Clinical Oncology 23:729s (2005). 58. Loprinzi CL, Levitt R, Sloan JA, Dakhil SR, Barton DL, Dalton RJ, Beardem JD, Mailliard JA, Tschetter LK, Novotny PJ: Medroxyprogestrone acetate (MPA) versus venlafaxine for hot flashes. Proc of the American Society of Clinical Oncology 23:732s (2005). 59. Dakhil S, Cosgriff T, Headley D, Boccia RV, Bandarinath BS: Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, I-03-002). Poster Session American Society of Clinical Oncology, June 2006, #3557. 60. Kelly K, Herbst RS, Crowley JJ, McCoy J, Atkins JN, Lara PN, Dakhil SR, Albain KS, Kim ES, Gandara DR: Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342. Oral presentation American Society of Clinical Oncology Meeting, June 2006, #7015. 61. Fidias P, Dakhil SR, Lyss AP, Loesch DM, Waterhouse D, Cunneen J, Ye Z, Tai F, Obasaju CK, Schiller JH: Updated report of a phase III study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs immediate second-line therapy with docetaxel (D) in advanced non-small cell lung cancer (NSCLC). Poster Discussion American Society of Clinical Oncology Meeting, June 2006, #7032.
Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 16

Other scholarly publications - Abstracts – (continued) 62. Ansell SM, Geyer SM, Kurtin PJ, Inwards DJ, Kaufmann SH, Flynn PJ, Morton RF, Luyun RF, Dakhil SR, Gross H, Witzig TE: Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group. Poster Discussion American Society of Clinical Oncology Meeting, June 2006, #7532. 63. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, Michalak JC, Salim M, Nikcevich DA, Dakhil SR, Fitch TR: Salvage chemotherapy with rituximab DHAP (RDHAP) for relapsed non-hodgkin’s lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group. General Poster Session American Society of Clinical Oncology Meeting, June 2006, #7574. 64. Hofman M, Morrow GR, Ranson SL, Jean-Pierre P, Dakhil SR, Moore T, Atkins J : Chemotherapy-naive cancer patients’ expectations of developing treatment-related side effects : A URCC CCOP study of 670 patients from community practices. Oral presentation American Society of Clinical Oncology Meeting, June 2006, #8509. 65. Jatoi A, Dakhil SR, Kugler JW, Rowland KM, Keit J, Verdirame JD, Novotny PJ, Sloan JA, Nguyen PL, Loprinzi CL: A placebo-controlled trial of etanerpcept, a tumor necrosis factor (TNF) inhibitor, in patients with the cancer anorexia/weight loss syndrome. North Central Cancer Treatment Group (NCCTG) trial N00C1. Poster Discussion American Society of Clinical Oncology Meeting, June 2006, #8534. 66. Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson P, Figueras C, Duane SF, Dakhil SR, Liu H, Loprinzi CL : A pilot, placebo-controlled evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG N03CA. American Society of Clinical Oncology Oral Presentation: 9001. (2007). 67. Jatoi A, Rowland KM, Sloan JA, Gross HM, Fishkin PAS, Kahanic SP, Novotny PJ, Schaefer PL, Dakhil SR, Loprinzi CL: Does tetracycline prevent or palliate epidermal growth factor receptor (EGFR) inhibitor-induced skin rash? American Society of Clinical Oncology Oral Presentation: LBA9006. (2007). 68. Haddock MG, Kim GP, Foster NR, Bollinger JW, Stella PJ, Kugler JW, Dakhil SR, Alberts SR, Martenson JA: Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer. American Society of Clinical Oncology (2007). 69. Alberts SR, Morlan BW, Kim GP, Pitot HC, Quevedo F, Dakhil SR, Gross HM, Merchan JR, Roberts LR: NCCTG phases II trial (N044J) of AXD2171 for patients with hepatocellular carcinoma – interim review of toxicity. American Society of Clinical Oncology (2007). 70. Inwards DJ, Hillman DW, Fishkin PAS, White WL, Morton RF, Dakhil SR, Nikcevich DA, Wender DB, Fitch TR, Kurtin PJ: Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantel cell lymphoma. American Society of Hematology (2007). 71. Joppert M, Boccia R, Dakhil S, Steis R: A preliminary report of a phase II trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer. American Society of Clinical Oncology: 18156. (2007). 72. Herbst RS, Chansky K, Kelly K, Atkins JN, Davies AM, Dakhil SR, Albain KS, Kim ES, Crowley JJ, Gandara DR: A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. Proc of the American Society of Clinical Oncology: #7545. (2007).
Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 17

Other scholarly publications - Abstracts – (continued) 73. Morrison V, Weller E, Haberman TM, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne R, Woda B, Fisher R, Peterson B, Horning SJ: Maintenance rituximab (MR) versus observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL) patients: An intergroup E4494/C9793 update. Proc of the American Society of Clinical Oncology: #8011. (2007). 74. Fidias P, Dakhil SR, Lyss AP, Loesch DM, Waterhouse D, Cunneen J, Chen R, Treat J, Obasaju CK, Schiller JH: Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: Updated report with survival. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18s):LBA7516. 75. Kottschade LA, Suman VJ, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ, Markovic SN : A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E. Proc of the American Society of Clinical Oncology: #9044. (2008). 76. Jatoi A, Foster NR, Egner J, Burch P, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy B, Alberts SR: Elderly patients with metatstatic esophageal/gastric cancer: A pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials. Proc of the American Society of Clinical Oncology: 26(May 20s) #9507. (2008). 77. Morrow GR, Jean-Pierre P, Roscoe JA, Heckler CE, Schwartzenberger PO, Giguere JK, Dakhil SR: A phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study. Proc of the American Society of Clinical Oncology: #9512. (2008). 78. Barton DL, LaVasseur B, Sloan JA, Stella PJ, Flynn K, Dyar M, Dakhil SR, Atherton PJ, Diekmann B, Loprinzi CL: A phase III trial of evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9. Proc of the American Society of Clinical Oncology: #9538. (2008). 79. Joppert M, Knapp M, Dakhil SR, Boccia RV, Steis R, Jones CM: A phase II trial of single-agent vinflunine as second-line treatment for advanced non-small cell lung cancer (An International Oncology Network Study, #I-05-009). Proc of the American Society of Clinical Oncology: #19033. (2008). 80. Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR, Alberts SR: Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy in gastric cancer. Proc of the American Society of Clinical Oncology: #4543. (2008). 81. Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K: S0536: Carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC), a SWOG phase II study. Journal of Clinical Oncology 27:15s, abst. #8015, 2009. 82. Sukov W, Miller DV, Dueck A, Tenner KS, Jenkins RB, Kaufman PA, Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA. Benefit of adjuvant treastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 intergroup adjuvant trial. Journal of Clinical Oncology 27:15s, abst #520, 2009. 83. Loprinzi CL, Qin R, Stella PJ, Rowland KM, Kugler JW, Dakhil SR, Jurgens DJ, Burger KN: Pregabalin in hot flashes in women: NCCTG trial N07C1. Journal of Clinical Oncology 27:15s, abst #9513, 2009.
Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 18

84. Markovic SN, Suman VJ, Kottschade LA, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ. A phase II trial of carboplatin and nab-paclitaxel (ABI-0007) in patients with unresectable stage IV melanoma, final data form N057E. Journal of Clinical Oncology 27:15s, abst #9055, 2009. 85. Hines S, Sloan JA, Atherton P, Perez E, Dakhil S, Johnson D, Reddy P, Dalton R, Mattar B, Loprinzi C. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. San Antonio Breast Cancer Symposium 2009; 2103 (N02C1). 86. Perez EA, Suman VJ, Davidson NE, Gralow J, Kaufman PA, Ingle JN, Dakhil SR, Zujewski JA, Pisansky TM, Jenkins RB. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER-2 positive breast cancer trial. General Session, 2009 San Antonio Breast Cancer Symposium (December 9-13, 2009). 87. Kirshner J, Dakhil SR, et al. Prevention of pegfilgrastim-induced bone pain (PIP): A URCC CCOP randomized, double-blind, placebo-controlled trial of 510 cancer patients. Proc of the American Society of Clinical Oncology: #9014. (2010) 1. Marymont JV, Dakhil SR, Brake D: Malpositioned hepatic artery catheters [letter]. J Clin Oncol 1986

Presentations to professional audiences:
1. Dakhil S, Ensminger W, Kindt G: Maintenance of constant CSF MTX levels with a totally implanted infusion system. Presented to the American Association for Cancer Research (AACR) 1980;21:149. 2. Ensminger W, Dakhil S, Cho K: Improved regional selectivity of hepatic arterial BCNU plus degradable starch microspheres. Presented to the American Society for Clinical Oncology (ASCO) 1981;22:382. 3. Keller J, Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R: Effective prolonged hepatic arterial chemotherapy using a totally implanted delivery system. Presented to the ASCO 1981;22:1788,C87. 4. Dakhil S, Ensminger W, Strother V, Kindt G, Chandler W, Greenberg H: Pharmacokinetics of intraventricular 5-fluoro-2'deoxyuridine (Fudr) in patients with meningeal neoplasia. Presented to the AACR 1981;22:178,C706. 5. Ensminger W, Dakhil S, Doan K, Cho K: Clinical pharmacology of dichloromethotrexate in hepatic arterial infusions. Presented to the AACR 1981;22:271,C1077. 6. Dakhil S, Hynes H, Kim P, Zatzkin J: Wichita community experience with the Infusaid pump for chemotherapy of liver malignancies. Presented to the American College of Physicians Kansas Regional Meeting, Kansas City, Missouri, February 1983. 7. Dakhil S, Hynes H, Zatzkin J: Wichita community experience with the implantable catheter (Port-A-Cath). Presented to the ASCO 1985;4:270,C1050.
Curriculum Vitae
Shaker R. Dakhil, M.D.-Page 19
Presentations to professional audiences: (cont)
8. Surgical Management of Carcinoma of the Rectum, 11/24/94, St. Francis Regional Medical Center, Surgery 9. Update on Lymphomas, 1/11/94, St. Francis Regional Medical Center, Medicine Conference. 10. Oncology Case Conference, 12/21/93, HCA-Wesley Medical Center. 11. Oncology Case Conference, 11/29/94, HCA-Wesley Medical Center. 12. Precancerous Syndrome, 4/14/95, Family Medicine Spring Program, Cancer Update, University of Kansas 13. Tamoxifen Prevention Program, STAR Program: Western Plains Regional Medical Center, Tumor Board 14. Phase II Trial Of A Weekly Taxol (T), 5-Fluorouracil (FU) And Leucovorin (LV) Regimen In Patients With Metastatic Breast Cancer: An Update Presented to the National Arab American Medical Association, Lebanon, 7/03/99. 15. Small Cell Lung Cancer, 10/06/99, ONS “Stars Over the Garden” Botanica Gardens, Wichita, KS. 16. Breast Cancer Prevention, 10/28/99, CCOP, Wichita, KS.
Presentations to lay audiences:

Emotional Components, 10/10/91, Victory in the Valley, Wichita, KS. What Every Doctor Wished Their Patients Knew About Cancer, 10/24/91, Victory in the Valley, Wichita, KS. Death With Dignity, 2/16/92, Newton Church. General Oncology, 2/19/92, Wichita State University Physical Therapy Students. Lebanon, 2/26/92, Collegiate High School International Day. General Oncology, 3/12/92, Ascension Lutheran Church, Wichita, KS. General Oncology, 5/28/92, Victory in the Valley, Wichita, KS. Surgical Management of Carcinoma of the Rectum, 11/24/93, St. Francis Regional Medical Center Surgery Tumor Conference. Oncology Case Conference, 12/21/93, Columbia Wesley Medical Center. Update on Lymphomas, 1/11/94, St. Francis Regional Medical Center Internal Medicine Rounds. Oncology Case Conference, 11/29/94, Columbia Wesley Medical Center. Presentations to lay audiences: (cont)
Precancerous Syndrome, 4/14/95, Family Medicine Spring Program, Cancer Update, UKSM-W. Breast Cancer: What You Should Know, What We Can Do. 3/10/00, Via Christi Cancer Center audio tape. Wichita, KS. Breast Cancer Awareness, 10/3/00, Junior League of Wichita, Inc. “I Can Cope.” Presentation to Memorial Hospital in McPherson 10/03/02. Breast Cancer Awareness, 11/07/02, Victory In the Valley Support Group.

Source: http://cckansas.cancercenter.cc/files/2011/05/Dakhil2.pdf